On the use of surrogate end points in randomized trials

Journal of the Royal Statistical Society. Series A: Statistics in Society

Volumn 163, Issue 1, 2000, Pages 15-28

  Begg, Colin B ^a   Leung, Denis H Y ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Randomized trials; Surrogate end points

Indexed keywords

EID: 0034360735     PISSN: 09641998     EISSN: None     Source Type: Journal    
DOI: 10.1111/1467-985X.00153     Document Type: Article

References (7)

1. Balslev, I., Axelsson, C. K., Zedeler, K., Rasmussen, B. B., Carstensen, B. and Mouridsen, H. T. (1994) The Nottingham Prognostic Index applied to 9149 patients from the studies of the Danish Breast Cancer Co-operative Group. Breast Cancer Res. Trtmnt, 32, 281-290.
2. Buyse, M. and Molenberghs, G. (1998) Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics, 54, 1014-1029.
3. Day, N. E. and Duffy, S. W. (1996) Trial design based on surrogate end points - application to comparison of different breast screening frequencies. J. R. Statist. Soc. A, 159, 49-60.
4. Fleming, T. R. and DeMets, D. L. (1996) Surrogate endpoints in clinical trials: are we being misled? Ann. Intern. Med., 125, 605-613.
5. Organizing Committee and Collaborators (1996) Breast cancer screening with mammography in women aged 40-49 years. Int. J. Cancer, 68, 693-699.
6. Prentice, R. L. (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Statist. Med., 8, 431-440.
7. Wald, N. J., Murphy, P., Major, P., Parkes, C., Townsend, J. and Frost, C. (1995) UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. Br. Med. J., 311, 1189-1193.